Biogen's $5.6B Rare Disease Grab & McCormick's $20B Flavor Merger

Описание: Biogen is making a massive splash in the rare disease space, announcing a definitive agreement to acquire Apellis Pharmaceuticals for $5.6 billion. The all-cash deal, priced at $41.00 per share, is designed to bolster Biogen's immunology portfolio and accelerate its expansion into nephrology. This marks a significant aggressive growth play for the biotech giant as it looks to secure its long-term pipeline. Also: McCormick and Unilever are combining their foods businesses to forge a global flavor juggernaut with an estimated $20 billion in combined 2025 revenue.; Private equity giant Carlyle is taking a majority stake in MAI Capital Management, valuing the wealth manager at over $2.8 billion.; CapVest Partners has officially completed its majority acquisition of leading German healthcare and pharmaceuticals company Stada.

---

Subscribe for daily M&A insights and deal analysis.

Sign up free: https://ololand.ai/signup?ref=youtube

Free tools:
CIM Analyzer: https://ololand.ai/tools/cim-analyzer
Valuation Calculator: https://ololand.ai/tools/valuation-ca...
Academic Paper Publisher: https://ololand.ai/tools/academic-pap...

#MergersAndAcquisitions #PrivateEquity #DueDiligence #DealStreetDaily #AI #SearchFunds